A holographic near-eye display device with multi-angle simultaneous illumination comprises a light source module, a spatial light modulator, a beam splitter, an eyepiece, and a master controller. The light source module emits parallel light at different angles and simultaneously illuminates and covers effective working area of spatial light modulator which, loaded with a hologram, modulates incident parallel light at different angles to form diffracted parallel light at different angles, that is, virtual images at different viewing angles. Parallel light at different angles illuminates spatial light modulator. After modulated and diffracted by calculated hologram on spatial light modulator, the diffracted image light is converged by second lens to form different viewpoints for human eye to view. In multi-angle simultaneous illumination, additional time-sharing control of illumination unit is not needed. When size and position of human eye pupil change, clear virtual image is always seen, achieving expanding the eyebox.
Colistin is an important last-resort antibiotic, but its production involves significant challenges due to the presence of impurities resulting from various analogs and the limited number of native producers. In response, disclosed are mutant Paenibacillus bacteria that produce Colicin A more efficiently and/or Colicin A that is of higher purity and/or has a cleaner metabolite background. The disclosed mutant bacteria are genetically engineered to inactivate expression of one or more biosynthetic gene clusters (BGCs), increase expression of one or more other BCGs, and/or increase expression of one or more L-DABA pathway genes.
Provided are compositions comprising chemically synthesized pseudaminic acid (Pse) conjugated to a carrier protein using the OPA chemistry, methods of using said compositions to stimulate immune responses in subjects and protect the vaccinated subjects from infections caused by Pse-producing A. baumannii.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Provided are a composition comprising a peptide conjugated to a TLR agonist, including TLR7 agonist 1v209, and methods of using the composition. The methods comprise administering the peptide-based vaccine conjugate to a subject. The peptide-based vaccine conjugate inhibits tumor growth and induces antigen-specific B and T cell responses in a subject.
The present invention relates to a compound for treating fungal disease, wherein said compound provide target-specific inhibition of fungal adhesion, biofilm formation, and filamentation without affecting their growth, at very low concentration. The compound of the present invention is selected from FDA approved drugs Cangrelor. Further, the present invention provides a composition comprising compound of the present invention and a pharmaceutically acceptable carrier. Further, the present invention provides a method of treating fungal infections using the compound and/or composition of the present invention. Furthermore, uses of the compound and/or composition is also being provided in the present disclosure.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A feed composition for spray drying comprises 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), leucine, an anti-IL-4Rα antibody or an antigen binding fragment thereof, and a solvent. A method of preparing a pharmaceutical composition comprises a step of spray drying the feed composition by such as a spray dryer. A pharmaceutical composition comprises or consists of: 2HPβCD, leucine, an anti-IL-4Rα antibody or an antigen-binding fragment thereof. Use of the feed composition according to any of the pharmaceutical composition or according to any of the manufacture of a medicament for preventing or treating a disease, preferably, the disease is one that can be treated by the anti-IL-4R antibody or an antigen binding fragment thereof.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 11/00 - Drugs for disorders of the respiratory system
7.
COMPOSITIONS AND METHODS FOR ENHANCING EFFICACY AND REDUCING ADVERSE EFFECTS FROM COVID VACCINATION
Disclosed are methods for constructing disulfide mimetics for late-stage cyclization of peptides. The disclosed method provides late-stage cyclization via thioacetalization of peptides containing two cysteine residues to form thioacetal group. These bonds are stable under acidic, basic, and reduced conditions. The reaction can use a broad range of cyclic ketones even acetone as crosslinkers. Trifluoroacetic acid (TFA) alone can act as both the catalyst and the sole solvent, thus allowing most peptide sequences to be cyclized via the disclosed method. The disclosed method provides a number of benefits and advantages, such as the use of TFA as both a robust catalyst of the reaction and the sole solvent needed, the easy availability of acetone and of diverse cyclic ketones for use as the reactant, the good chemoselectivity and tolerance of native peptide to the reaction, and the fact that the resulting crosslinks are structural mimetics of disulfides.
232222-alkyl, SCHF-alkyl, S-alkyl, S-aryl, etc., onto tryptophan residue (s) of a peptide, in particular a native peptide. Generally, the late-stage peptide modification method includes: (i) maintaining a reaction mixture at a sufficient temperature for a sufficient period of time to form a product. The reaction mixture contains the peptide being modified, which contains one or more tryptophan residues; a sulfynyl reagent; and a solvent. The product formed in step (i) contains a sulfenylated peptide, where the sulfenylation is on at least one of the one or more tryptophan residues of the peptide.
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C40B 50/08 - Liquid phase synthesis, i.e. wherein all library building blocks are in liquid phase or in solution during library creationParticular methods of cleavage from the liquid support
A fusion peptide comprising a coronavirus HR2-derived peptide fused to an ACE2-derived peptide or a lipopeptide comprising the fusion protein and cholesterol is a broad spectrum inhibitor of coronavirus.
A computer-implemented bone-implant system evaluation method for application of mesh-free analysis of a bone-implant system for evaluation of performance of a bone-implant system for an implant implanted within the bone structure at an anatomical site, said method comprising (i) receiving a set of bone structure data set, wherein set of bone structure data includes data indicative of the bone structure at an anatomical site; (ii) inputting an implant data set and inputting the position of the implant data set, wherein the implant is selected based upon the biomechanical requirements for the anatomical site and the position and of the implant data set is indicative of the position of the implant with respect to the anatomical site, wherein implant data set includes data representative of the geometry and materials properties of the implant; (iii) creating a bone-implant model, wherein said bone implant-model includes a mesh-free model of trabecular bone at the anatomical site wherein the bone-implant model is formed from the bone structure data set from step (i) and the implant data set from step (ii), and wherein the mesh-free model of trabecular bone is indicative of the trabecular bone structure of the bone structure at the anatomical site; and (iv) determining a biomechanical result based upon computer simulated loading of the bone-implant system based upon mesh-free analysis of the bone-implant model, wherein the biomechanical result includes data based on the displacement of the implant relative to the bone of bone-implant model.
G06F 30/20 - Design optimisation, verification or simulation
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
12.
Dinuclear platinum (II) red emitters for OLED applications
−1. The Pt(II) complexes disclosed herein can be included in organic light-emitting devices, such as organic light-emitting diodes (“OLEDs”), for use in commercial applications. OLEDs containing these red-emitting Pt(II) complexes can have current efficiency and/or external quantum efficiency that are comparable or higher than commercially available red emitters and prolonged operational lifetime, such as a LT95 at 1000 nits>9000 h for a red OLED.
H10K 50/11 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
H10K 50/12 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers comprising dopants
H10K 71/12 - Deposition of organic active material using liquid deposition, e.g. spin coating
H10K 71/13 - Deposition of organic active material using liquid deposition, e.g. spin coating using printing techniques, e.g. ink-jet printing or screen printing
H10K 71/16 - Deposition of organic active material using physical vapour deposition [PVD], e.g. vacuum deposition or sputtering
SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION, DBA SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (USA)
Inventor
Hui, Shu Yuen Ron
Tan, Siew Chong
Mi, Chunting Chris
Abstract
Disclosed is a system for stabilizing a power distribution network. The network is supplied at least partially by a renewable energy source. The system comprises a bidirectional AC-DC power conversion system between a supply 5 side distribution network and a load side grid. for converting a supply side AC voltage, at a supply side frequency. to a load side DC voltage; a voltage regulator for regulating the load side DC voltage; and a supply side control loop comprising at least one of a frequency control loop and a voltage control loop for making a measurement of a respective one of the supply side frequency and 10 supply side AC voltage. and controlling bidirectional power transmission between the bidirectional AC-DC power conversion system and one or more DC loads connected to the load side grid. based on the measurement from the respective frequency control loop and/or voltage control loop.
H02J 3/32 - Arrangements for balancing the load in a network by storage of energy using batteries with converting means
H02J 3/16 - Circuit arrangements for ac mains or ac distribution networks for adjusting voltage in ac networks by changing a characteristic of the network load by adjustment of reactive power
H02J 3/38 - Arrangements for parallelly feeding a single network by two or more generators, converters or transformers
H02M 7/797 - Conversion of AC power input into DC power outputConversion of DC power input into AC power output with possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only
14.
A MICROFLUIDIC PIPELINE FOR ISOLATION AND ANALYSIS OF SINGLE VIRUSES
Advanced Biomedical Instrumentation Centre Limited (China)
Centre for Immunology & Infection Limited (China)
Inventor
Shum, Ho Cheung
Poon, Lit Man
Nan, Lang
Lai, Man Yuk Alison
Abstract
The subject invention pertains to a microfluidic pipeline which enables isolation and analysis of single viruses. Single viruses are encapsulated and manipulated within microfluidic droplets. The subject invention further pertains to the amplification of single viral genomes are amplified and confined within the droplets, followed by extraction and isolation of the single-droplet contents for sequencing analysis.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
Disclosed are methods and compositions for use in preparing dynamic biological macromolecules for high-resolution cryo-electron microscopy or cryo-electron tomography imaging. The compositions contain a metallo-supramolecular branched polymer with a positive zeta potential, containing a hydrophilic polymer segment, a chelating chemical group, and a metal ion. The hydrophilic polymer segment is covalently bonded to the chelating chemical group that is in turn bonded to the metal ion via a dative bond. The methods and compositions can be used to improve particle distribution in vitreous ice and/or to change particle orientations in vitreous ice. Accordingly, the methods and compositions can be utilized to improve particle distribution for high resolution structure determination using single-particle cryo-EM.
G01N 1/42 - Low-temperature sample treatment, e.g. cryofixation
G01N 23/225 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes
16.
METHODS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION SKELETAL SEQUELAE
Methods for treating or preventing a skeletal sequelae of a coronavirus infection in a subject in need thereof, the method comprising administering a therapeutically effective amount of an endothelin receptor antagonist to the subject, with the proviso that the endothelin receptor antagonist is not co-administered with dapagliflozin or niclosamide. The skeletal sequelae can include one or more of arthralgia, viral arthritis, osteopenia, osteochondral damage, and osteoporosis.
A method and systems for making predictions based on a classifierare provided. The method includes receiving a multivariate input having feature variables; making prediction based on a comonotone-independence Bayes classifier (CIBer) via performing conditional probability mass function on the feature variables; and outputting a predictive class. The making prediction based on the comonotone-independence Bayes classifier (CIBer) includes a joint encoding to artificially insert ordering in categorical features. The joint encoding is configured to preserve inherent dependence among the categorical features.
G06F 18/2415 - Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on parametric or probabilistic models, e.g. based on likelihood ratio or false acceptance rate versus a false rejection rate
18.
BUILDING BLOCKS FOR DIFFICULT PEPTIDE SYNTHESIS AND METHOD OF MAKING THEREOF
Building block structures containing N, O/S-benzylidene acetal dipeptide (NBD) are described. The unique core structure of NBD can effectively convert those difficult peptide/proteins sequence into the easy ones, allowing smooth synthesis of those challenging targets. Further, the production of NBDs is highly robust, and it can be scale up facilely, which can facilitate the research and development of tailor-made peptides/proteins in the future.
A holographic near-eye display device capable of multi-angle simultaneous illumination, comprising a light source module, a spatial light modulator (130), a beam splitter (120), an eyepiece, and a master controller (150). The light source module is used for emitting parallel light of different angles to simultaneously illuminate and cover an effective working region of the spatial light modulator (130). The spatial light modulator (130) is loaded with a hologram and used for modulating incident parallel light of different angles to form diffracted parallel light of different angles, i.e., virtual images of different viewing angles. The parallel light of different angles illuminates the spatial light modulator (130) and is modulated and diffracted via a computer-generated hologram on the spatial light modulator (130), and diffracted image light is converged by a second lens (140) to form different viewpoints for viewing by human eyes. The multi-angle simultaneous illumination does not require additional time-sharing control of an illumination unit, and when the size and position of human eye pupils change, a clear virtual image can always be seen, thereby achieving the objective of expanding an eyebox.
A method of treating a coronavirus infection in a subject in need thereof, the method including administering a therapeutically effective amount of an endothelin receptor antagonist to the subject, with the proviso that the endothelin receptor antagonist is not co-administered with dapagliflozin or niclosamide.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A steerable arm for use in endoscopic surgical procedures. The steerable arm cut from a tube of nitinol to provide flexibility and resilience by the structure into which the tube is cut. Typically, the cut tube comprises a spiralling coil, the loops of which are in contact on one lateral side of the tube and the tube is bent to open apart the loops on the other lateral side. The material which the tube is made of is capable of retaining memory of the bend. This provides a bias for restoring the tube to the bend whenever a force causing the tube to flex is removed.
A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
The subject invention pertains to a new class of compounds, N-acryloylindole (NAIs), and methods of using NAIs as cysteine-reactive probes for proteome-wide cysteine profiling and imaging of thiol oxidative modifications. NAIs are capable of imaging oxidized thiols in cells facing oxidative stress by confocal fluorescence microscopy. NAIs can capture populations of cysteines, particularly those involved in gene expression and regulation.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
23.
DIAMOND PARTICLE-BASED PHYSICAL UNCLONABLE FUNCTION MATERIAL, AND PREPARATION METHOD THEREFOR AND USE THEREOF
DONGGUAN INSTITUTE OF OPTO-ELECTRONICS, PEKING UNIVERSITY (China)
Inventor
Chu, Zhiqin
Zhang, Tongtong
Wang, Qi
Wang, Zhongqiang
Abstract
The present invention provides a diamond particle-based physical unclonable function material, and a preparation method therefor and a use thereof. The material comprises a monocrystalline silicon substrate, and diamond particles having silicon vacancy color centers and grown in situ on the monocrystalline silicon substrate. Preparation of the diamond particles on the silicon substrate relates to a random process, which is a key requirement for manufacturing a physical unclonable function label. According to the present invention, the scattering spectra, morphology features and spatial position relationship of the diamond particles are used as fingerprint information of the diamond physical unclonable function material. Due to extreme heat resistance, mechanical, chemical and light stabilities of a diamond material, the high-robustness label in the present invention can meet the requirements of many practical uses in various environments, and has practical commercial value in huge anti-counterfeit markets such as electronic components, medical packages, vehicles, and luxury goods.
CENTRE FOR VIROLOGY , VACCINOLOGY AND THERAPEUTICS LIMITED (China)
Inventor
Zhou, Jie
Chiu, Man Chun
Li, Cun
Yuen, Kwok Yung
Abstract
Provided is a robust nasal organoid culture system and fully characterized 2D and 3D in-vitro generated organoids, and methods of using the organoids. The nasal organoids contain a population of differentiated nasal epithelial cells having cellular heterogeneity and molecular markers similar to mature nasal epithelial tissue. Improved methods for generating two-dimensional and three-dimensional nasal organoids are also provided. The methods generally require a two-phase culture system, i.e., expansion and differentiation culture. The provided nasal organoids are suitable for recapitulating nasal tissue complexity for modeling respiratory diseases, studying barrier function and drug delivery, high-throughput drug screening, and assessing the effects of pathogens and environmental toxins on the nasal respiratory epithelium.
A rechargeable aqueous Mg battery is composed of a Mg metal anode, a solid-state aqueous polymer-based electrolyte, and an intercalation-type Prussian blue analogue cathode for ion storage. During battery operation, the Mg anode undergoes dissolution and deposition, while Mg ions in the electrolyte inserts and extracts from the cathode lattice, thereby releasing energy during discharge and storing energy during charge.
The subject invention pertains to a new method for measuring the elastic properties of microfibers by rope-coiling. Rope-coiling refers to the buckling of a slender elastic fiber caused by axial compression. A continuous flow microfluidic method enables the high-throughput measurement of the elasticity of microfibers by rope-coiling, where sample loading and unloading are not needed between consecutive measurements. In certain embodiments the coiling radius can be directly proportional to the elastic modulus of the fiber, facilitating calibration to measure fiber elasticity for high-throughput applications. Throughput can be thousands of times higher than that of a tensile tester, making possible an in situ, on-line measurement in a microfluidic production line, which couples the making of microfibers and the measurement of elasticity on the same line. The new method can also measure certain fibers with local variations in elasticity.
Genetically modified zebrafish, in which mutation combinations frequently identified in human AML are stably expressed in the stem cell population of the fish, are provided. The combination of mutations result in morphologic, cytochemical and molecular changes of its blood cells that are remarkably similar to those in human AML. The zebrafish model provides a foundation for the study of AML initiation and progression and a high throughput in vivo drug screening platform to identify personalized therapies for AML based on specific mutation combinations. The method of drug screening includes contacting embryos or adult fish containing mutations as disclosed herein, with a test agent, at test concentrations and test intervals to determine the therapeutic effect if any, of the test agent.
The invention relates to the field of biomedicine. In particular, the invention relates to a live strain of Staphylococcus aureus and uses thereof. More particularly, the invention relates to a live strain of Staphylococcus aureus which lacks adenosine synthase A (AdsA) activity, to a vaccine against Staphylococcus aureus infection comprising said live strain, and a method for preventing and/or treating Staphylococcus aureus infection in a subject by administering said live strain.
The subject invention pertains to a system for the electrochemical conversion of nitrate to ammonia. The electrolysis is carried out using a cell with a working electrode having a CuDATA molecular catalyst absorbed on carbon black. The system is effective for the conversion of waste nitrate solutions to ammonia. The conversion occurs with a high faraday efficiency of about 98%.
C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
Advanced Biomedical Instrumentation Centre Limited (China)
Inventor
Chow, Shing Fung
Low, Kam Hung
Wong, Si Nga
Abstract
The subject invention pertains to cocrystals of dexamethasone (DEX) and a benzenediol cocrystal composed of a 1:1 molar ratio of DEX and the benzenediol. The benzenediol can be catechol (CAT) or resorcinol (RES). The DEX and benzenediol cocrystal are formed by grinding crystalline DEX where the crystalline benzenediol are combined in the 1:1 molar ratio. Grinding can be performed at room temperature. Cocrystals can be thermally annealed or exposed to humidity to enhance cocrystal formation. The DEX−CAT or DEX-RES cocrystals can be included in a medicament for use in treatments for allergies, asthma, rhinitis, cancer, diabetes, anemia, ulcers, and viral infections. The DEX−benzenediol cocrystal can be sieved to provide particles that are in the range of 10 to 45 μm that can be used for intranasal administration with improved dissolution performance.
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
C07C 37/84 - SeparationPurificationStabilisationUse of additives by physical treatment by crystallisation
A61K 9/00 - Medicinal preparations characterised by special physical form
The subject invention pertains to a Cas9 protein with an amino acid mutation at residues 888, 889, or a combination thereof of a WED domain and/or residues 988, 989, or a combination thereof of a PI domain. The subject invention can further pertain to a Cas9 protein with mutations at amino acid positions N986, D987, L988, L989, or any combination thereof. The subject invention also pertains to a method of enhancing the activity of KKH-SaCas9. In addition, a method of machine learning-based in silico screens for genome editing protein engineering is provided, including steps of populating a predictive machine learning model with an input dataset comprising empirical measurements of on-target activities of sgRNAs paired with a screening library of genome editing enzyme variants; running the predictive machine learning model with predefined parameters; and evaluating performance of the predictive machine learning model.
Disclosed is a method of obtaining preparing an extract of Spatholobus suberectus Dunn, which contains total flavonoid and proanthocyanidins. The disclosure relates to a method for extracting an active fraction from Spatholobus suberectus. Also provided is the SSP, the active fraction, and a composition thereof. Further provided is a method of treating viral diseases such as COVID-19 disease caused by SARS-CoV-2, and use of the SSP and the active fraction in the manufacture of preparations for prevention and/or treatment of a viral disease.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
LABORATORY FOR SYNTHETIC CHEMISTRY AND CHEMICAL BIOLOGY LIMITED (China)
Inventor
Che, Chi Ming
Fu, Zhiwen
Leung, Yiu Chung Gulice
Abstract
Synthetic agrimol B and derivatives thereof ( "compounds" ) that have anticancer properties are disclosed. Methods for synthesizing the compounds with an overall yield ≥ 7% are disclosed. Pharmaceutical formulations in forms suitable for the delivery of the compounds to a subject in need thereof are disclosed. Methods of using the compounds for treating a cancer, reducing a cancer, or treating or ameliorating one or more symptoms associated with a cancer, such as non-small-cell lung cancer, in a subject are also disclosed. The methods include (i) administering to the subject the pharmaceutical formulation containing one or more compounds, for one or more times. The compounds can selectively kill cancer cells and/or cancer stem cells over non-cancerous cells by inducing mitochondria dysfunction and/or inhibiting ER to Golgi trafficking in the cancer cells and/or cancer stem cells.
C07C 49/84 - Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
C07C 49/83 - Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups polycyclic
C07C 45/45 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by condensation
C07C 45/61 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups
Disclosed in the present invention are benzothiazole compounds as well as a preparation method therefor and the use thereof. The compounds have a great inhibition effect on SARS-CoV-2 and can be used for resisting the novel coronavirus. (I)
C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
Centre for Virology, Vaccinology and Therapeutics Limited (China)
Inventor
Yuan, Shuofeng
Chan, Fuk Woo Jasper
Yuen, Kwok Yung
Abstract
The subject invention pertains to compounds and methods of using said compounds to target the multi-functional papain-like protease (PLpro) domain of the viral Nsp3, specifically F0213, F0326, and F0393 that can have broad anti-coronavirus activity, including SARS-CoV-2, MERS-CoV, and coronaviruses hCoV-229E and hCoV-OC43. F0213, F0326, and F0393 can possess a dual therapeutic functionality that suppress CoV replication via blocking viral polyprotein cleavage, as well as promote antiviral immunity by antagonizing the PLpro deubiquitinase activity.
CENTRE FOR VIROLOGY , VACCINOLOGY AND THERAPEUTICS LIMITED (China)
Inventor
Kok, Kin Hang
Yuen, Chun Kit
Yuen, Kwok Yung
Wong, Wan Man
Abstract
Provided are engineered, replication-deficient influenza viruses that are infectious and stimulate broadly-cross protective immunity against multiple different influenza strains. Also provided are compositions and methods for providing protective immune responses against influenza. The methods deliver compositions of intact, replication-deficient influenza viruses by intradermal administration in an amount effective to elicit or stimulate a cross-protective immune response to influenza viruses in the recipient following a single administration. Because the engineered influenza viruses are non-replicating, they are safe and effective in immunocompromised subjects. Also provided are methods for delivering co-stimulatory molecules, growth factors, adjuvants and/ or cytokines together with the non-replicating influenza viruses.
Laboratory for Synthetic Chemistry and Chemical Biology Limited (China)
Inventor
Che, Chi Ming
Wang, Tingting
Wang, Haixu
Abstract
Methods for asymmetric cis-dihydroxylation (“AD”) of quinones to produce cis-diols of quinones with high yield (i.e. a yield ≥30%) and high enantioselectivity (i.e. an enantiometric excess ≥30%) are disclosed. The method uses an iron-based catalyst, such as one or more Fe(II) complexes, as the catalyst, and can be performed under mild reaction conditions (e.g. a temperature ≤50° C. at 1 atom in open air). The method generally includes: (i) maintaining a reaction mixture at a temperature for a period of time sufficient to form a product, where the reaction mixture contains a quinone, one or more iron-based catalyst(s), and a solvent, and where the product contains a chiral cis-diol. Optionally, the method also includes adding an oxidant into the reaction mixture prior to and/or during step (i), such as a hydrogen peroxide solution.
C07C 50/30 - Quinones containing groups having oxygen atoms singly bound to carbon atoms with polycyclic non-condensed quinoid structure
C07C 50/34 - Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having three rings
C07C 50/36 - Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having four or more rings
38.
IRON-CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES
LABORATORY FOR SYNTHETIC CHEMISTRY AND CHEMICAL BIOLOGY LIMITED (China)
Inventor
Che, Chi Ming
Wang, Tianting
Wang, Haixu
Abstract
ciscisciscis-diol. Optionally, the method also includes adding an oxidant into the reaction mixture prior to and/or during step (i), such as a hydrogen peroxide solution.
C07C 29/48 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups
C07C 35/14 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing six-membered rings with more than one hydroxy group bound to the ring
B01J 31/28 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of the platinum group metals, iron group metals or copper
39.
NEUTRALIZING ANTIBODIES AGAINST COVID-19 AND METHODS OF USE THEREOF
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (China)
Inventor
Chen, Zhiwei
Zhou, Runhong
Zhou, Biao
Luo, Mengxiao
Chen, Bohao
Abstract
Disclosed are compositions and methods using antibodies and antibody fragments that bind SARS-CoV-2 spike protein or receptor binding domain (RBD). Generally, the CDRs of the antibodies and antigen binding fragments comprise: (a) the three light chain CDRs selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, and 64; and (b) the three light chain CDRs selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, and 63.In some forms, the antibody is a bispecific antibody.
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (China)
Inventor
Zhao, Hanjun
Yuen, Kwok-Yung
Abstract
Antiviral peptides and formulations thereof are described for use in treating or preventing one or more symptoms of coronavirus infections. Peptides derived from human beta defensin 2 have been shown to have antiviral properties against different variants of coronavirus including cross-linking viral particles, blocking cell-to-cell fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via intranasal route to prevent or alleviate one or more symptoms of coronavirus infections such as reducing the syncytial formation and lung damage.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Provided are a composition comprising a peptide conjugated to a TLR agonist, including TLR7 agonist 1v209, and methods of using the composition. The methods comprise administering the peptide-based vaccine conjugate to a subject. The peptide-based vaccine conjugate inhibits tumor growth and induces antigen-specific B and T cell responses in a subject.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
Disclosed is a compact, lightweight hydraulic manipulation system used for underwater applications consisting of two parts: a modulus hybrid underwater manipulator and a compact lightweight hydraulic control framework. The system is used for general underwater work such as underwater sampling, hyperbaric welding, and marine aquaculture.
Described herein are two-coordinated d10 metal carbene complexes containing (i) Cu (I), Ag (I), or Au (I), (ii) a pyrazine-fused NHC ligand or a pyridine-fused NHC ligand, and (iii) a carbazole ligand, a pyrido [2, 3-b] indole ligand, or a pyrido [3, 4-b] indole ligand. The radiative properties of the compounds can be controlled by thermally activated delayed fluorescence. The emission colors of the complexes can be tuned by using carbazoles with varying donor strength. Also described are methods of using the complexes.
Provided are two fully humanized Δ42PD1-specific mAbs, specifically huCH101 and huCH34 at 97.0% humanness by CDR grafting. Provided is a method of using huCH101 and/or huCH34 to treat subjects in need of Δ42PD1-specific mAb, including subjects with cancer and/or infection.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides an antibacterial and antiviral copper-containing stainless steel, and a preparation method for and the use of a stainless steel conforming to the composition thereof. The copper-containing stainless steel comprises a stainless steel matrix and a copper-rich phase evenly distributed in the stainless steel matrix, wherein the copper content of the copper-containing stainless steel is 6-30 wt%. The preparation method therefor comprises the manufacturing of a small stainless steel product mainly using powder metallurgy technology, and the manufacturing of a large stainless steel sheet, bar or pipe mainly using a composite process without significant thermal deformation. Compared with a traditional antibacterial stainless steel, the composition design of the present invention contains sufficient copper-rich precipitated phases, such that the antibacterial and antiviral copper-containing stainless steel of the present invention can achieve both a good killing effect on bacteria and a virus killing capacity comparable with that of pure copper, can be used for preparing the integral body or the whole of parts such as cutters, elevator buttons, railings, handrails, door handles and cups, and can effectively kill bacteria and viruses existing on the surfaces thereof.
The present invention relates to a compound for treating fungal disease, wherein said compound provide target-specific inhibition of fungal adhesion, biofilm formation, and filamentation without affecting their growth, at very low concentration. The compound of the present invention is selected from FDA approved drugs Cangrelor. Further, the present invention provides a composition comprising compound of the present invention and a pharmaceutically acceptable carrier. Further, the present invention provides a method of treating fungal infections using the compound and/or composition of the present invention. Furthermore, uses of the compound and/or composition is also being provided in the present disclosure.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61K 9/00 - Medicinal preparations characterised by special physical form
LABORATORY FOR SYNTHETIC CHEMISTRY AND CHEMICAL BIOLOGY LIMITED (China)
Inventor
Che, Chi-Ming
You, Tingjie
Abstract
Described herein is an iron(II)-phthalocyanine catalyzed C—H bond amination of alkyl azides. The catalyst is effective to produce intramolecular amination of saturated C—H bonds in moderate to excellent yields and the methods are tolerant of a wide scope of substrates. The methods described are useful for the synthesis of natural products derivatives and for the late-stage functionalization of pharmaceuticals.
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
49.
AEROSOLIZED VITAMIN A FOR MANAGEMENT OF COVID–19-RELATED OLFACTORY DYSFUNCTION
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (China)
HALCYON LIFE SCIENCES TECHNOLOGY LIMITED (China)
Inventor
Chung, Wai Hin
Hung, Ivan Fan Ngai
Sze, Kong Hung
Sridhar, Siddharth
Yan, Bingpeng
Yuen, Kwok Yung
Abstract
Disclosed are compositions and methods useful for management of rhinological, neurological, or psychiatric complaints and disorders. The rhinological, neurological, or psychiatric complaint and disorder can be one that affects the normal human neurosensory, neurocognitive, or neuropsychiatric functions, including but not limited to olfactory dysfunction. The complaint or disorder can be one that is related to coronavirus disease 2019 (COVID-19), including but not limited to olfactory dysfunction. Disclosed are compositions including a vitamin A solution and an essential oil mixture. The vitamin A solution can be a vitamin A compound and a nontoxic solvent, such as a pharmaceutically acceptable solvent. The vitamin A compound can be at a concentration of from 10,000 to 120,000 international units (IU). The vitamin A solution and the essential oil mixture can be in a ratio of from 4: 1 to 1: 4 in the composition. The composition of vitamin A solution and essential oil mixture can be aerosolized and administered via the subject's nose.
The subject invention pertains to methods and compositions for treating hypertension. In specific embodiments, the methods comprise administering KSD179019 to a subject in need of hypertension treatment. In further embodiments, the methods comprise administering a KSD179019 analog or derivative to a subject in need of hypertension treatment. Also provided are methods to design and manufacture KSD179019 analogs and derivatives with enhanced and prolonged anti-hypertensive therapeutic efficacy.
Embodiments of the present invention provide a video timing motion nomination generation system and a method, which process, by means of an encoder, video features that are extracted from an inputted video so as to obtain video encoding features having global information, and extract corresponding segment features of interest from the video encoding features by means of a plurality of pre-trained nomination segments to provide to a decoder; the decoder generates segment features on the basis of the segment feature of interest corresponding to each nomination segment and a nomination feature corresponding to each pre-trained nomination segment, and provides same to a prediction module; and the prediction module generates a timing motion nomination result on the basis of the segment features from the decoder. The solution of the embodiments of the present invention can effectively capture global context information of a video and obtain video encoding features that have a stronger representation ability. Moreover, by introducing several learnable nomination segments to extract feature sequences of corresponding positions from the video encoding features for subsequent prediction, which improves training convergence speed and greatly reduces computational burden.
An entry/exit detection apparatus has two separate signal transmitters (T1,T2) with a signal blocking device (SBD) in-between them. Based on this apparatus, a virtual line (16) is established for detecting whether an object or a person (A) crossed the virtual line (16) and entered or exited from a place or vehicle which has the virtual line (16) at its entrance. The place may be a building, market, shop, restaurant, bank, school, lift (elevator), room, or car. When the object or person (A) with the portable device crosses this virtual line, the motion is detected by the detector monitoring signal from the two transmitters. The portable device will be able to detect and recognize it has crossed the virtual line automatically based on the signals received from these two signal transmitters.
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (China)
Inventor
Zhou, Jie
Chiu, Man Chun
Li, Cun
Yuen, Kwok Yong
Abstract
Methods for obtaining a population of differentiated alveolar cells, differentiated alveolar cells in the form of alveolar organoids generated by the methods and uses for the differentiated alveolar organoids are provided. The methods include digesting long-term expanding lung organoids (LO) into single cells (i.e., dissociated cells), and suspension culturing the dissociated cells in distal differentiation (DD) cell culture media in a non-adherent plate for an effective amount of time. Alveolar organoids includes a population of AT1 and AT2 cells and in suspension culture exhibit an apical-out polarity and include abundant cytoplasmic lamellar bodies and microvilli. The alveolar organoids can be utilized alone or in combination with 2D and 3D AWO, rebuilt the human respiratory epithelium in culture plates for studying biology and pathology of human respiratory system, including, but not limited to, the study of COVID-19 respiratory diseases.
Provided are compositions comprising chemically synthesized pseudaminic acid (Pse) conjugated to a carrier protein using the OPA chemistry, methods of using said compositions to stimulate immune responses in subjects and protect the vaccinated subjects from infections caused by Pse-producing A. baumannii.
The present invention provides a video action detection method based on an end-to-end framework, and an electronic device. The end-to-end framework comprises a backbone network, a positioning module, and a classification module. The method comprises: performing, by the backbone network, feature extraction on a video clip to be detected to obtain a video feature map of said video clip, wherein the video feature map comprises feature maps of all frames in said video clip; extracting the feature map of a key frame from the video feature map by the backbone network, obtaining an actor location feature from the feature map of the key frame, and obtaining an action category feature from the video feature map; determining an actor location by the positioning module according to the actor location feature; and determining, by the classification module, the action category corresponding to the actor location according to the action category feature and the actor location. The video action detection method provided by the present invention is relatively low in complexity, and can achieve better detection performance.
Disclosed is a fiber-based hydrogel containing an aqueous hydrogel containing biocompatible microfibers having a high aspect ratio length to diameter suspended in water, the biocompatible microfibers mechanically interlocked. By simply adjusting the fiber aspect ratio, the fiber-based hydrogels can tune a considerable range of mechanical properties and drug release rates for clinical use. The fiber-based hydrogel has favorable biocompatibility and accelerated tissue regeneration ability demonstrated by a mice excision skin model.
A novel medical image generation approach synthesizes thin-cut computerized tomography (CT) images from thick-cut CT ones as inputs. First thick-cut CT images are obtained by maximizing the pixel-wise intensity of five or more than five continuous thin-cut ones after image registration. Second, the obtained thick-cut CT images are fed into a generator block which adopts an encoder-decoder architecture, where each thick-cut image is encoded into low-dimensional embedding space before decoding into multiple thin-cut ones. Third, a discriminator focuses on distinguishing original real thin-cut images from synthetic thin-cut images. An adversarial mechanism between the generator and discriminator causes the discriminator's output to provide an effective gradient update of the network parameters for the generator to increasingly improve the generator's ability to synthesize higher-quality thin-cut images and in turn promotes the discriminator's discriminating capability.
Disclosed is a three dimensional classification system for recognizing cross-sectional images automatically containing a processor that executes: rescaling a plurality of cross-sectional images, and feeding the rescaled plurality of cross-sectional images into two branches; feeding the rescaled plurality of cross-sectional images into a first branch for performing a plurality of convolutions on the rescaled plurality of cross-sectional images directly to learn features for distinguishing phases; feeding the rescaled plurality of cross-sectional images into a second branch for reducing resolution, then performing a plurality of convolutions on the reduced resolution plurality of cross-sectional images to learn features for distinguishing phases; and concatenating convolutional output channels from the two branches to fuse global and local features, on which two fully-connected layers are stacked as a classifier to recognize cross-sectional volumetric images accurately and quickly.
SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION, DBA SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION (USA)
Inventor
Hui, Shu Yuen, Ron
Tan, Siew Chong
Mi, Chunting, Chris
Abstract
Disclosed is a system for stabilizing a power distribution network. The network is supplied at least partially by a renewable energy source. The system comprises a bidirectional AC-DC power conversion system between a supply 5 side distribution network and a load side grid, for converting a supply side AC voltage, at a supply side frequency, to a load side DC voltage; a voltage regulator for regulating the load side DC voltage; and a supply side control loop comprising at least one of a frequency control loop and a voltage control loop for making a measurement of a respective one of the supply side frequency and 10 supply side AC voltage, and controlling bidirectional power transmission between the bidirectional AC-DC power conversion system and one or more DC loads connected to the load side grid, based on the measurement from the respective frequency control loop and/or voltage control loop.
H02J 3/18 - Arrangements for adjusting, eliminating or compensating reactive power in networks
H02J 3/16 - Circuit arrangements for ac mains or ac distribution networks for adjusting voltage in ac networks by changing a characteristic of the network load by adjustment of reactive power
B60L 53/50 - Charging stations characterised by energy-storage or power-generation means
61.
DINUCLEAR PLATINUM EMITTER COMPLEXES AND METHODS OF MAKING AND USING THEREOF
Described herein are dinuclear platinum (II) emitter complexes and their methods of making and using thereof. The design of the dinuclear platinum (II) emitters results in short radiative lifetimes and high quantum yields. The dinuclear platinum (II) emitter complexes can be used to fabricate blue emitting OLEDs.
Described herein are compounds containing palladium (II), as the central metal atom, and tetradentate [N^C^C^N] ligands. The compounds are charge neutral, and feature a donor-acceptor structure where a pendant substituted amino group (such as unsubstituted diphenylamine or substituted diphenylamine) and a heteroaryl group (such as pyridine group) serve as donor and acceptor, respectively. This donor-acceptor structure introduces a set of low-energy singlet and triplet charge-transfer excited states with small energy separation allowing for efficient thermally activated delayed fluorescence to take place.
C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
Platinum (II) complexes ( "Pt (II) complexes" ) that can emit in the red and/or deep red regions and methods of making and using thereof are described. These Pt (II) complexes can have dinuclearity with close Pt-Pt contact and close interplanar distance, allowing for high emission quantum yield, such as > 50%, short emission lifetime, such as < 3 μs, and high radiative decay rate, such as in the order of 10 5s -1. The Pt (II) complexes disclosed herein can be included in organic light-emitting devices, such as organic light-emitting diodes ( "OLEDs" ), for use in commercial applications. OLEDs containing these red-emitting Pt (II) complexes can have current efficiency and/or external quantum efficiency that are comparable or higher than commercially available red emitters and prolonged operational lifetime, such as a LT95 at 1000 nits >9000 h for a red OLED.
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)
64.
DEVICES AND METHODS FOR ORIENTING A SURGICAL DEVICE
Devices and methods are provided that simplify and improve placement of stabilizing orthopedic pins, wires, and/or screws in the pelvis in minimally invasive surgery. Provided is a surgical instrument guide containing an adjustable friction clamp for positioning and securing a cannula, and a probe with a blunt, nonpenetrating tip. The probe and a surgical instrument held by the friction clamp are oriented at right angles to one another. In use, the blunt probe is introduced through a small incision and advanced by blunt dissection until the blunt tip is positioned at a desired anatomical landmark on the surface of the pelvis. A cannula inserted through the friction clamp is advanced until the tip of the cannula is within 2 cm of the blunt tip of the probe; an orthopedic pin, wire, and/or screw can then be inserted through the cannula to provide stabilization. The blunt probe may be cannulated.
Provided are an Eye Movement analysis with Hidden Markov Model (EMHMM) with co-clustering, an Eye Movement analysis with Switching Hidden Markov Models (EMSHMM) to analyze eye movement data in cognitive tasks involving stimuli with different feature layouts and cognitive state changes, a switching hidden Markov model (SHMM) to capture a participant's cognitive CN state transitions during the task and an EMSHMM to assess preference decision-making tasks with two or more cognitive states. The EMSHMM provides quantitative measures of individual differences in cognitive behavior/style, making a significant impact on the use of eye tracking to study cognitive behavior across disciplines.
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 5/16 - Devices for psychotechnicsTesting reaction times
66.
SURGERY DEVICE WITH PATIENT-SPECIFIC FIBULA MALLEOLUS CAP
Described are fibula malleolus caps and surgery devices with fibula malleolus caps. The fibula malleolus caps may be patient-specific fibula malleolus caps. The devices with patient-specific fibula malleolus caps overcome the sliding and rotational errors during fibula flap harvesting. A comparative clinical study demonstrates that the fibula malleolus cap enhances the accuracy of fibula flap harvesting, leading to accurate location and angulation of simultaneous dental implants.
An electromechanical sensor and a method of sensing an object or a tactile input using the sensor. The sensor includes: a base provided with a magnetic sensor arranged to detect a change in magnetic flux at the position of the magnetic sensor; a flexible film adjacent to the magnetic sensor; and a magnetic element provided on the flexible film; wherein the magnetic element is arranged to move relative to the magnetic sensor when the flexible film is reversibly deformed by an external force applied to the flexible film.
G01R 33/06 - Measuring direction or magnitude of magnetic fields or magnetic flux using galvano-magnetic devices
G01B 7/14 - Measuring arrangements characterised by the use of electric or magnetic techniques for measuring distance or clearance between spaced objects or spaced apertures
G01B 7/24 - Measuring arrangements characterised by the use of electric or magnetic techniques for measuring the deformation in a solid, e.g. by resistance strain gauge using change in magnetic properties
G01L 1/12 - Measuring force or stress, in general by measuring variations in the magnetic properties of materials resulting from the application of stress
G01V 3/08 - Electric or magnetic prospecting or detectingMeasuring magnetic field characteristics of the earth, e.g. declination or deviation operating with magnetic or electric fields produced or modified by objects or geological structures or by detecting devices
G01D 5/14 - Mechanical means for transferring the output of a sensing memberMeans for converting the output of a sensing member to another variable where the form or nature of the sensing member does not constrain the means for convertingTransducers not specially adapted for a specific variable using electric or magnetic means influencing the magnitude of a current or voltage
CENTRE FOR VIROLOGY, VACCINOLOGY AND THERAPEUTICS LIMITED (China)
Inventor
Zhao, Hanjun
Yuen, Kwok-Yung
Abstract
Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting in viral resistance. Preferably, the antiviral compositions contain P16 or a P16-like peptide which can both inhibit viral fusion and endosomal acidification to prevent viral entry through the endocytic pathway. The antiviral compositions can be used in methods of treating diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A (H1N1) pdm09 virus, avian influenza A (H7N9) virus, and the non-enveloped rhinovirus. The compositions are administered in a subject in need thereof in an effective amount to reduce or prevent viral replication in the subject, and thus reduce one or more symptoms of disease, disorder, or illness associated with virus.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A steerable arm (301) for use in endoscopic surgical procedures. The steerable arm (301) cut from a tube of nitinol to provide flexibility and resilience by the structure into which the tube is cut. Typically, the cut tube comprises a spiralling coil (707), the loops of which are in contact on one lateral side of the tube and the tube is bent to open apart the loops on the other lateral side. The material which the tube is made of is capable of retaining memory of the bend. This provides a bias for restoring the tube to the bend whenever a force causing the tube to flex is removed.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes
70.
Method for peritoneal metastatic cell detection and isolation thereof
Provided herein is a method for the detection and isolation of metastatic cells from a sample obtained from a subject. Also provided is a device comprising a microchip for use in the method. Also provided is a method of isolating the metastatic cells for culture and characterization. Provided herein is a kit for the method therein.
Live attenuated viruses for protection against the novel coronavirus Sars-CoV-2 are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza A or B virus (LAIVA/B), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-A/B-Sars-CoV-2-CoV2Ag. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33℃. Compositions including the chimeric virus also provided as a co-composition with a LAIVA/B. The DelNS1-A/B-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. The co-compositions can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2 and influenza A and/or B.
A nanostructured composite membrane filter for rapid water purification and methods for preparing the nanostructured composite membrane filter are provided. The nanostructured composite membrane includes a silver layer having a plurality of silver functionalized nanofibers for disinfecting microorganisms of water, and a chemical modified layer having a plurality of chemical modified nanofibers for removing impurities from the water. The plurality of silver functionalized nanofibers includes a plurality of polyvinyl alcohol (PVA) nanofibers coated with polydopamine (PDA) and silver, and each of the plurality of chemical modified nanofibers includes a polymer matrix such as polyvinyl alcohol (PVA) and anionic polyelectrolytes such as poly (sodium styrenesulfonate) (PSSNa) for capturing metal ions of the water.
A power converter circuit includes: a direct current (DC) side; a first passive network; a first current switching network; at least one floating capacitor; a second current switching network; a second passive network; and an alternating current (AC) side. The first passive network is connected between the DC side and the first current switching network for linking the DC side and the first current switching network. The first current switching network comprises at least four serially linked switches for switching the power converter circuit between switching cycles. The at least one floating capacitor is connected to the first current switching network. The second current switching network comprises two pairs of switches for providing an interface between the first current switching network and the second passive network. The second passive network is connected between the second current switching network and the AC side.
H02M 7/797 - Conversion of AC power input into DC power outputConversion of DC power input into AC power output with possibility of reversal by static converters using discharge tubes with control electrode or semiconductor devices with control electrode using devices of a triode or transistor type requiring continuous application of a control signal using semiconductor devices only
74.
Amyloid precursor protein as a diagnostic marker for biliary atresia
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
75.
LIVE ATTENUATED SARS-COV-2 VIRUS IMMUNOGENIC COMPOSITIONS, METHODS OF MAKING AND USING
Provided are a live attenuated SAR-CoV-2 virus (Ca-DelMut-LASV), compositions comprising the live attenuated virus and methods for increasing an immune response to Sars-CoV-2. Ca-DelMut-LASV is characterized by a deletion of the amino acid sequence NSPRRARSVA (SEQ ID NO: 1), which represents a deletion of amino acids 665-705 of the wild type SARS-CoV-2 spike. Ca-DelMut-LASV additionally includes the following mutations relative to wild type SARS-CoV-2: an A578V mutation in the NSP3 protein; a P25L mutation in the spike protein; a V367F in the spike protein; an F20S in the E protein and a V62L mutation in ORF8.
POSTECH ACADEMY-INDUSTRY FOUNDATION (Republic of Korea)
VERSITECH LIMITED (China)
Inventor
Kim, Dong Pyo
Kim, Ji Tae
Lee, Hyune Jea
Abstract
The present invention relates to a method for controlling an ultrafast chemical reaction using a microfluidic reactor, and more specifically, the present invention relates to a method for controlling an ultrafast chemical reaction such as the Fries rearrangement reaction and the like by using a microfluidic reactor by the 3D metal printing technique.
The NS1 protein of influenza virus is a key virulent element with multi-functional roles in virus replication and acts as a strong interferon (IFN) antagonist. A live attenuated virus (LAIV) is provided using a master backbone, which contains the influenza B (HK8038) virus and includes a deletion of the NSI coding region (DelNS1). The LAIV is based on novel adaptive mutations, which support DelNS1 influenza B live attenuated virus (LAIV) replication in vaccine producing cells. DelNS1 influenza B LAIV shows spontaneous cold adaption with preference to grow at 30-33° C. but restriction at 37-39° C. The LAIV can be used to protect a subject, against a lethal challenge of antigenic distant influenza B viruses. DelNS1 LAIV with adaptive mutations for growing in vaccine producing systems is an important strategy for making highly attenuated and immunogenic live attenuated influenza vaccines with the ability to induce broad cross protective immunity for seasonal influenza.
Provided herein are novel ortho-Phthalaldehyde (OPA) containing linkers (OPA-L) and the use of OPA-L for the preparation of Antibody-drug conjugate (ADC) via the formation of Phthalimidine through the reaction of primary amine on antibody (e.g., residue of Lysine) and ortho-Phthalaldehyde. The advantage of this OPA-L is high reactivity and can be applied in different types of antibodies to form stably-linked conjugates. The use of OPA-L for the preparation of ADC is advantageous for mild and wide condition of conjugation, for instance, low percentage of organic solvent required, wide range of pH and temperature can be used.
C07D 207/452 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
C07C 235/78 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07C 233/61 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
79.
APPARATUS AND METHOD FOR MULTIPLEXED ROTATING IMAGING BIOASSAYS
Systems and method for versatile multiplexed spinning/rotating bioassays are provided. This bioassay platform can take the advantage of the high-speed spinning motion, which naturally provides on-the-fly cellular imaging at the rate that cannot be reached by the conventional cameras or laser-scanning techniques, but ultrafast imaging modalities. More importantly, the functionalized solid substrates derived from the disk substrate can be compatible with adherent cell culture as well as biochemically-specific cell-capture, which can now be assayed with ultrafast imaging modalities at an ultra-high-speed line-scan rate of >10 MHz. Large-format spinning high-throughput imaging assay could thus be a potent tool for scaling both the assay throughput as well as content/multiplexity as demanded in many applications, e.g. drug discovery, and rare cancer cell screening.
Devices that convert heat into electricity, and methods for a fabrication of the same are provided. The asymmetric thermo-electrochemical capacitor uses a GO-based positive electrode and a battery-type negative electrode to open up the operating voltage window and enhance the electrical discharge capacity for converting low-grade heat into electricity with excellent efficiency, fast thermo-charging time, and stable cycles. The thermo-electrochemical device includes a carbon-based positive electrode, a conductive polymer or a metal-organic framework as negative electrode, a current collector, and a porous separator.
A computer implemented method for searching electronic documents, and associated system and computer program product. The method includes receiving an input representing an example-based search query and processing the input. The method also includes determining, for each of the electronic documents, a relevance score between the input and the corresponding electronic document. The determination is based on, at least, textual similarity between the input and the corresponding electronic document, topical similarity between the input and the corresponding electronic document, as well as linkage relationship in a linkage network of the plurality of electronic documents. The method also includes determining, based on the determined relevance scores, a search result containing one or more of the electronic documents. The search results will be provided to the user.
Provided herein is formulations, systems and methods in which one or more compounds that inhibit AP2M1interaction with a protein motif utilized for trafficking of a viral protein are used to treat a broad range of viral infections. An example of such a compound is N- (p-amylcinnamoyl) anthranilic acid (ACA). Viral infections that are suited to such an approach include those caused by RNA viruses in which virally encoded proteins utilized for transport of viral RNA into the cell nucleus include a YxxØ motif, wherein Ø represents an amino acid with a bulky hydrophobic side chain and x can be any amino acid. Examples of suitable viruses include various strains of influenza virus and coronavirus (e.g. SARS-CoV-2).
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
C07C 229/58 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho- position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
A compact, lightweight hydraulic manipulation system used for underwater applications is disclosed. The system comprises a hybrid underwater manipulator and a hydraulic control framework comprising at least two compensating soft bladders. The system is used for general underwater work such as underwater sampling, hyperbaric welding, and marine aquaculture.
Disclosed are soft origami actuators with embedded optical waveguides and underwater manipulator applications.An underwater manipulator with a gripper is also presented, actuated with the same soft origami actuators. The main contributions of this disclosure include: 1) coupling of stretching and bending are eliminated by combing origami soft actuators and special designed optical waveguide; 2) the optical waveguide is designed such that no cladding is needed which largely reduces fabrication complexity; and 3) a new hybrid underwater manipulator is described, with redundant position feedback for accuracy and dexterous underwater applications.
Compositions and immunoassays for detecting SARS-CoV-2 antigen-specific antibodies in a biological sample are provided. The compositions are antigens from SARS-CoV-2 such as the proteins N, M, S, S1, S2', NSP1, ORF3a, ORF3b, ORF7a, ORF7b and ORF8, fused to a light emitting protein. The compositions are useful in immunoassays for detecting antibodies to the SARS-CoV-2 antigens. A preferred immunoassay is the luciferase immunoprecipitation systems (LIPS) to detect SARS-CoV-2 antigen-specific antibodies with high sensitivity and specificity. The current or present exposure or infection with SARS-CoV-2 can be detected and/or diagnosed using the disclosed compositions and methods. Typically, the presence and/or elevated amount of SARS-CoV-2 antibodies in the individual's biological sample compared to a control is indicative of current or past exposure or infection with SARS-CoV-2 as discussed herein.
This invention is related to a dimming method and a dimming circuit for light-emitting-diode (LED) assemblies driven by nominally non-dimmable passive LED drivers. An LED system usually consists of an LED driver and an LED assembly. The LED driver normally provides a current source for the LED assembly. The LED assembly consists of individual LED devices or several LED modules mounted on a heatsink. LED devices or modules can be connected in series or in parallel or a combination of both. This invention involves the combined use of a controller and circuit for providing dimming function in the LED assembly driven by a passive LED driver without closed-loop current regulation. By using one or more controllable bypass-switches across sections of the LED strings in an LED assembly, the power of one or more groups of LED devices or LED modules can be cut off in order to dim the LED system. When the voltage of LED is reduced by closing the bypass switch or switches, a uniqueness of this invention is that the per-unit increase in the output current of the passive driver must be smaller than the per-unit voltage reduction of the LED load, resulting in reduction of power consumption in the LED load for dimming purpose. The dimming control can take turns to cut off the power of different groups of LED devices or modules in different times in order to share operating burden and preserve lifetime of the LED assembly. The invention is particularly suitable for, but not restrict to, lighting applications in smart lampposts in which smart wireless communication systems are mounted on the same lampposts as the LED assemblies and dimming signals can be received wirelessly. The advantages of this invention are that the dimming function is provided in the LED assembly rather than in the LED drivers, and the dimming circuit can be linked to smart control in emerging smart lampposts.
Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Provided herein is DNA vaccine and composition comprising PD1-based TWIST1. Also provided is a method for inducing TWIST1-specific T cell response by administering a PD1-based TWIST1 vaccine. Also provided is a method for inducing TWIST1-specific T cell response by administering a PD1-based TWIST1 vaccine and an immune checkpoint inhibitor.
Disclosed soluble PD-1 (sPD-1) proteins and nucleic acids, and therapeutic compositions comprising sPD-1 proteins and nucleic acids, for enhancing immunity of a subject against coronavirus infection. Disclosed are soluble PD-1 fusion proteins that include a soluble PD-1 protein fragment and an antigenic protein fragment, preferably where the antigenic protein fragment comprises a coronavirus protein fragment. In some forms, the coronavirus protein fragment is derived from a coronavirus receptor binding domain (RBD) or a coronavirus nucleoprotein (N). In some forms, the sPD-1 proteins, nucleic acids, and compositions are formulated as a vaccine composition. Also disclosed are methods for treating a subject at risk of or suffering a coronavirus infection.
Live attenuated viruses for protection against the novel coronavirus Sars-CoV-2 are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza virus (LAIV), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain preferably shows spontaneous cold adaption with preference to grow at 30-33℃. The DelNS1-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2.
Live attenuated viruses for protection against the novel coronavirus which emerged in Wuhan, Hubei Province of China, designated as Sars-CoV-2 by the World Health Organization (WHO) are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza virus (LAIV), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-Sars-CoV-2-CoV2Ag. The DelNS1-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33° C. The DelNS1-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. DelNS1-Sars-CoV-2-CoV2Ag is an important strategy for making highly attenuated and immunogenic live attenuated vaccines with the ability to induce protective immunity against Sars-CoV-2.
Devices and methods related to a graphene oxide-based membrane are provided. A method comprises immersing graphene oxide-based layers in a water-based solution, stirring the water-based solution in a swirling motion until the graphene oxide-based layers each physically curve, adding a crosslinker to the water-based solution to cause the formation of saccate graphene oxide-based cells that are connected to each other via channels, and stacking the saccate graphene oxide-based cells on a substrate to form a graphene oxide-based membrane.
System and method of ultrasound imaging methodology are provided. The system and method can include directing an array to transmit sets of cascaded titled ultrasound waves towards a tissue sample, decoding reflected signals through summing, subtracting, and delay operations. The reflected signals can be reconstructed to provide a final decoded output.
Methods and compounds for preventing and/or treating Zika virus (ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
97.
Compositions and methods for broad-spectrum antiviral therapy
AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-α signaling, and is not a result of activation of the hosts innate immune response. Broad antiviral activity of AM580 and structurally related compounds is a due to modulation of lipogenesis so as to correct disregulation of this pathway in virus-infected cells, via inhibition of nSREPBP.
The compositions and the use thereof for treating hypertension are provided, wherein the compositions comprise KSD179019, a derivative thereof or a pharmaceutically accceptable salt thereof. Also provided are methods to design and manufacture KSD179019 analogs and derivatives with enhanced and prolonged anti-hypertensive therapeutic efficacy.
A nanostructured composite membrane filter for rapid water purification and methods for preparing the nanostructured composite membrane filter are provided. The nanostructured composite membrane includes a silver layer having a plurality of silver functionalized nanofibers for disinfecting microorganisms of water, and a chemical modified layer having a plurality of chemical modified nanofibers for removing impurities from the water. The plurality of silver functionalized nanofibers includes a plurality of polyvinyl alcohol (PVA) nanofibers coated with polydopamine (PDA) and silver, and each of the plurality of chemical modified nanofibers includes a polymer matrix such as polyvinyl alcohol (PVA) and anionic polyelectrolytes such as poly (sodium styrenesulfonate) (PSSNa) for capturing metal ions of the water.
B01D 69/00 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor
100.
COMPOSITIONS AND METHODS FOR IMPROVING VACCINATION OF HYPORESPONSIVE INDIVIDUALS
Compositions and methods are provided that enhance the ability of low- or non-responding individuals undergoing renal replacement therapy to develop a protective antibody response following immunization. A toll-like receptor agonist is applied at or near the vaccination site and left in place for a period of time following vaccination, for example with a Hepatitis B vaccine.
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
patents
